STAT+: J&J sues Samsung over a contract breach for a Stelara biosimilar

As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one manufacturer of striking a “surreptitious” deal that could arguably reduce…